Inhalation Sciences (ISAB) Status Update summary

Platform technology and partnerships

• Added best-in-class inhalation platform technology, collaborating with institutions like Fraunhofer, Karolinska Institute, and King's College London.

• Secured a $500,000 grant for initial project phases, supporting further development.

Market opportunity and backlog

• Estimated addressable market remains at EUR 135 million, with international expansion potential.

• Non-pharma order backlog stands at approximately 45 million.

Financial status and outlook

• No need to reach breakeven or require further capital injection at this stage.

• Project timing and guidelines updates expected by November, with ongoing evaluation of dissolution methods.